The Urology Care Foundation is working to create new resources to provide support, hope and guidance to prostate cancer ...
Have you been struggling with frequent urination, interrupted sleep, or suffering from erectile dysfunction, and wondered if ...
Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...
Timed with National Men’s Health Month, the Prostate Monster ad campaign shines a light on quality-of-life issues associated with benign prostatic hyperplasia or BPH—a condition affecting millions of ...
Equity through efficiency: Automating patient to trial matching using AI and OncoLLM. This is an ASCO Meeting Abstract from the 2025 ASCO Quality Care Symposium. This abstract does not include a full ...
Novartis, a leading global innovative medicines company and the official pharmaceutical partner of the NFL, today announced the launch of "Relax, it's a blood test," a new national prostate cancer ...
Talzenna plus Xtandi showed a 14-month survival improvement for HRR gene-mutated metastatic castration-resistant prostate cancer, supported by TALAPRO-2 trial data. Nubeqa approval for metastatic ...
ZERO Prostate Cancer (ZERO), announces the 2026 Veterans' Action Convening, a national gathering committed to strengthening prostate cancer care, support, and outcomes for veterans. Taking place ...
Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results